With over a thousand enrolled to participate in clinical trials, the Faculdade de Medicina da Federal University of Minas Gerais (UFMG) in Belo Horizonte, started applying this Friday, 25th, the first vaccine against Covid-19 developed with totally Brazilian technologies and inputs and financed by national institutions. The immunizer is still in the testing phase.
Named SpiN-Tec MCTI UFMG, the vaccine was produced at the Vaccine Technology Center (CTVacinas) at UFMG in partnership with Fiocruz Mines. With the authorization of National Health Surveillance Agency (Anvisa) for clinical tests, the search for volunteers took place shortly after approval by the National Research Ethics Commission (Conep), a group that evaluates ethics in research protocols with humans. CTVacinas received in less than ten days more than a thousand people registered as volunteers for the screening.
Pre-clinical tests, carried out in the laboratory and on animals, confirmed the effectiveness of the vaccine and had their results published in August by the journal Nature